Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden
Sign Up to like & getrecommendations! Published in 2018 at "Scandinavian Journal of Urology"
DOI: 10.1080/21681805.2018.1426039
Abstract: Abstract Objectives: The aim of this study was to examine the use of abiraterone and enzalutamide, two oral novel antiandrogens (NOVAs), in men with prostate cancer (PCa) in Sweden. Materials and methods: This cross-sectional study… read more here.
Keywords: use; study; prostate cancer; men prostate ... See more keywords
Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5583
Abstract: 5583Background: FDA has approved three novel AAs [Apalutamide(A), Darolutamide(D) and Enzalutamide(E)] in combination with Androgen deprivation therapy ( ADT) for treatment of (nmCRPC) patients (pt... read more here.
Keywords: novel; treatment; antiandrogens aas; novel antiandrogens ... See more keywords